KalVista Pharmaceuticals, Inc.

NASDAQ:KALV

Biotechnology

Healthcare
$27.00 +0.00%

+$0.00 today

Market cap
$1.44B
Beta
-0.11
P/E (TTM)
-9.9
EPS (TTM)
-$2.74
52W Low $9.83High $27.00

Volume 4.26M

Average 3.47M

KALV EBITDA Margin

EBITDA as a percentage of revenue.

KalVista Pharmaceuticals, Inc.NASDAQ: KALV

EBITDA Margin · Q4 FY2026 · quarter ended Dec 2025

EBITDA Margin at -42.9%

EBITDA Margin was -42.9% in Q4 FY2026. On a trailing-twelve-month basis it was -101.1%.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 3 analysts of 60.0% for the fiscal year ending Dec 2026, up from -204.6% in FY2026.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterDec 2025
-42.9%+265.3 pp QoQ
Last fiscal yearDec 2025
-204.6%— YoY
LTMDec 2025
-101.1%— YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year—+264.6 pp—
3 years—+264.6 pp—
5 years+264.6 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2026
-204.6%
Year-over-year change
—
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How KALV compares with its peers on the latest reported figures

  • KALV's LTM Dec 2025 EBITDA Margin of -101.1% is the 3rd highest of the 9 companies compared; the peer median is -157.1%.
KALV Competitors Peer median
EBITDA Margin for KALV and competitors
Company Period LTM level YoY 3-year change
OMEROmeros CorporationLTM Mar 2026939.0% ——
RIGLRigel Pharmaceuticals, Inc.LTM Mar 202643.8% +19.9 pp+89.5 pp
KALVKalVista Pharmaceuticals, Inc.LTM Dec 2025-101.1% ——
ADCTADC Therapeutics S.A.LTM Mar 2026-105.1% +22.1 pp-58.4 pp
PRTAProthena Corporation plcLTM Mar 2026-129.0% -45.6 pp-1804.0 pp
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026-185.2% +738962.6 pp+3203.1 pp
GOSSGossamer Bio, Inc.LTM Mar 2026-304.0% -275.3 pp—
BCYCBicycle Therapeutics plcLTM Mar 2026-333.1% +482.9 pp+448.9 pp
VSTMVerastem, Inc.LTM Mar 2026-387.1% +1063.3 pp+2084.9 pp
OLMAOlema Pharmaceuticals, Inc.FY2025— ——
Peer median (excluding KALV) -157.1%+22.1 pp+269.2 pp

Competitors are the stored peer set for KALV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Apr 2022
FY2023
Apr 2023
FY2024
Apr 2024
FY2025
Apr 2025
FY2026
Dec 2025
Revenue000073.62M
Cost of Revenue0086.17M06.08M
Gross Profit00(86.17M)067.54M
Gross Margin————91.7%
Research & Development70.17M80.28M86.17M71.71M55.64M
Selling, General & Admin26.45M30.6M54.28M116.29M183.74M
Operating Expenses96.61M110.87M54.28M188M239.38M
Depreciation & Amortization564K718K816K941K1.45M
EBITDA(80.75M)(94.37M)(134.28M)(173.33M)(150.62M)
EBITDA Margin————-204.6%
Operating Income(96.61M)(110.87M)(140.45M)(188M)(171.84M)
Operating Margin————-233.4%
Interest Income1.09M2.23M3.9M6.44M8.68M
Interest Expense0005.79M19.34M
Other Income / Expenses14.27M17.96M5.35M7.94M420K
Income Before Tax(82.34M)(92.91M)(135.1M)(180.05M)(171.42M)
Pre-Tax Margin————-232.9%
Income Tax Expense00(8.45M)3.39M(7.13M)
Net Income(82.34M)(92.91M)(126.64M)(183.44M)(164.29M)
Net Margin————-223.2%
EPS (Basic)(3.36)(3.33)(3.44)(3.69)(3.23)
EPS (Diluted)(3.36)(3.33)(3.44)(3.69)(3.23)
Weighted Avg Shares24.47M27.89M36.79M49.65M50.9M
Weighted Avg Shares (Diluted)24.47M27.89M36.79M49.65M50.9M

KalVista Pharmaceuticals, Inc.

NASDAQ:KALV

Intrinsic Alpha fair value

Locked

Current Price

$27.00

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.